Active substance
Results for the substance dolutegravir abacavir lamivudine
2 results
About this active substance
The combination of dolutegravir, abacavir, and lamivudine is used for the treatment of human immunodeficiency virus (HIV) infection in adults and adolescents. It works by inhibiting the integration of viral DNA into the host genome, preventing virus replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, insomnia, headaches, and elevated liver enzyme levels.
This combination is contraindicated in patients with hypersensitivity to any of the components or severe hepatic impairment. Its use also requires regular monitoring of liver and renal function.
This medication is an effective option for managing HIV infection, helping to reduce viral load and improve patients' quality of life.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, insomnia, headaches, and elevated liver enzyme levels.
This combination is contraindicated in patients with hypersensitivity to any of the components or severe hepatic impairment. Its use also requires regular monitoring of liver and renal function.
This medication is an effective option for managing HIV infection, helping to reduce viral load and improve patients' quality of life.